AGL PE Ratio & Valuation,Is AGL Overvalued

AGL Relative Valuation

AGL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AGL is overvalued; if below, it's undervalued.

Historical Valuation

agilon health inc (AGL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.05 is considered Undervalued compared with the five-year average of -27.21. The fair price of agilon health inc (AGL) is between 4.92 to 6.91 according to relative valuation methord. Compared to the current price of 0.72 USD , agilon health inc is Undervalued By 85.38%.

Relative Value

Fair Zone

4.92-6.91

Current Price：0.72

85.38%

Undervalued

-1.14

-0.16

EV/EBITDA

agilon health inc. (AGL) has a current EV/EBITDA of -0.16. The 5-year average EV/EBITDA is 105.31. The thresholds are as follows: Strongly Undervalued below -884.85, Undervalued between -884.85 and -389.77, Fairly Valued between 600.39 and -389.77, Overvalued between 600.39 and 1095.47, and Strongly Overvalued above 1095.47. The current Forward EV/EBITDA of -0.16 falls within the Historic Trend Line -Fairly Valued range.

-0.10

EV/EBIT

agilon health inc. (AGL) has a current EV/EBIT of -0.10. The 5-year average EV/EBIT is -89.00. The thresholds are as follows: Strongly Undervalued below -287.40, Undervalued between -287.40 and -188.20, Fairly Valued between 10.21 and -188.20, Overvalued between 10.21 and 109.41, and Strongly Overvalued above 109.41. The current Forward EV/EBIT of -0.10 falls within the Historic Trend Line -Fairly Valued range.

0.05

agilon health inc. (AGL) has a current PS of 0.05. The 5-year average PS is 1.93. The thresholds are as follows: Strongly Undervalued below -2.08, Undervalued between -2.08 and -0.08, Fairly Valued between 3.93 and -0.08, Overvalued between 3.93 and 5.94, and Strongly Overvalued above 5.94. The current Forward PS of 0.05 falls within the Historic Trend Line -Fairly Valued range.

-2.93

P/OCF

agilon health inc. (AGL) has a current P/OCF of -2.93. The 5-year average P/OCF is 601.66. The thresholds are as follows: Strongly Undervalued below -1928.64, Undervalued between -1928.64 and -663.49, Fairly Valued between 1866.81 and -663.49, Overvalued between 1866.81 and 3131.96, and Strongly Overvalued above 3131.96. The current Forward P/OCF of -2.93 falls within the Historic Trend Line -Fairly Valued range.

-2.57

P/FCF

agilon health inc. (AGL) has a current P/FCF of -2.57. The 5-year average P/FCF is 679.53. The thresholds are as follows: Strongly Undervalued below -4696.44, Undervalued between -4696.44 and -2008.45, Fairly Valued between 3367.51 and -2008.45, Overvalued between 3367.51 and 6055.49, and Strongly Overvalued above 6055.49. The current Forward P/FCF of -2.57 falls within the Historic Trend Line -Fairly Valued range.

agilon health inc (AGL) has a current Price-to-Book (P/B) ratio of 0.97. Compared to its 3-year average P/B ratio of 4.49 , the current P/B ratio is approximately -78.30% higher. Relative to its 5-year average P/B ratio of 3.85, the current P/B ratio is about -74.72% higher. agilon health inc (AGL) has a Forward Free Cash Flow (FCF) yield of approximately -27.63%. Compared to its 3-year average FCF yield of -7.88%, the current FCF yield is approximately 250.67% lower. Relative to its 5-year average FCF yield of -5.53% , the current FCF yield is about 399.54% lower.

0.97

P/B

Median3y

4.49

Median5y

3.85

-27.63

FCF Yield

Median3y

-7.88

Median5y

-5.53

Competitors Valuation Multiple

The average P/S ratio for AGL's competitors is 1.24, providing a benchmark for relative valuation. agilon health inc Corp (AGL) exhibits a P/S ratio of 0.05, which is -96.01% above the industry average. Given its robust revenue growth of -1.08%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of AGL decreased by 62.16% over the past 1 year. The primary factor behind the change was an decrease in Revenue Growth from 1.45B to 1.44B.

The secondary factor is the Margin Expansion, contributed -4.24%to the performance.

Overall, the performance of AGL in the past 1 year is driven by Revenue Growth. Which is more sustainable.

-1.08%

1.45B → 1.44B

Revenue Growth

-4.24%

-8.02 → -7.68

Margin Expansion

-56.84%

-2.13 → -0.92

P/E Change

-62.16%

1.90 → 0.72

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is agilon health inc (AGL) currently overvalued or undervalued?

What is agilon health inc (AGL) fair value?

AGL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of agilon health inc (AGL) is between 4.92 to 6.91 according to relative valuation methord.

How does AGL's valuation metrics compare to the industry average?

What is the current P/B ratio for agilon health inc (AGL) as of Dec 15 2025?

As of Dec 15 2025, agilon health inc (AGL) has a P/B ratio of 0.97. This indicates that the market values AGL at 0.97 times its book value.

What is the current FCF Yield for agilon health inc (AGL) as of Dec 15 2025?

As of Dec 15 2025, agilon health inc (AGL) has a FCF Yield of -27.63%. This means that for every dollar of agilon health inc’s market capitalization, the company generates -27.63 cents in free cash flow.

What is the current Forward P/E ratio for agilon health inc (AGL) as of Dec 15 2025?

As of Dec 15 2025, agilon health inc (AGL) has a Forward P/E ratio of -1.14. This means the market is willing to pay $-1.14 for every dollar of agilon health inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for agilon health inc (AGL) as of Dec 15 2025?

As of Dec 15 2025, agilon health inc (AGL) has a Forward P/S ratio of 0.05. This means the market is valuing AGL at $0.05 for every dollar of expected revenue over the next 12 months.

AGL Valuation